European Hematology Association Congress (EHA) | Conference

RG6234 Shows Promise as Monotherapy in Heavily Pretreated Multiple Myeloma
June 24, 2022

Data presented at the 2022 European Hematology Association Congress demonstrated potential utility of the bispecific antibody RG6234 in a previously treated cohort of patients with multiple myeloma.

Early Findings Highlight Promising Outcomes With REGN5458 in Relapsed/Refractory Multiple Myeloma
June 22, 2022

Patients with relapsed/refractory multiple myeloma experienced promising responses with REGN5458.

Similar OS and Transplantation Observed With Decitabine vs Chemo in Geriatric AML
June 20, 2022

Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.

Venetoclax Plus Obinutuzumab Yield PFS Improvement in Untreated CLL, With or Without Ibrutinib
June 16, 2022

Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.

Quizartinib Added to Chemo Boosts Overall Survival in FLT3-ITD–positive AML
June 13, 2022

The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.

Epcoritamab Yields Durable Responses in Relapsed/Refractory LBCL
June 13, 2022

An expansion cohort from the phase 2 EPCORE NHL-1 trial demonstrated strong efficacy of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Shaji Kumar, MD, Details Toxicities With Daratumumab Plus Lenalidomide/Dexamethasone in Frontline MM
July 14, 2021

At EHA 2021, Shaji Kumar, MD, reviews the toxicity profile of daratumumab plus lenalidomide and dexamethasone for patients with transplant-ineligible multiple myeloma in the first-line setting.

Shaji Kumar, MD, Reviews PFS With Daratumumab-Containing Therapy in Frontline Myeloma
July 06, 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of a daratumumab combination in patients with multiple myeloma.

Shaji Kumar, MD, Discusses 5-Year Overall Survival Data for MM Daratumumab Combo in the MAIA Study
June 29, 2021

At EHA 2021, Shaji Kumar, MD, reflects on the significance of 5-year data from the MAIA study of daratumumab plus lenalidomide/dexamethasone in patients with newly diagnosed multiple myeloma.

Shaji Kumar, MD on the Impact of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed MM
June 24, 2021

Shaji Kumar, MD, talks about 5-year follow-up data regarding the use of daratumumab, lenalidomide, and dexamethasone in patients with multiple myeloma who are not eligible for transplant.